PeDRA 2026: Nemolizumab phase II data show long-term symptom relief for children aged 2 to 11 years with moderate-to-severe atopic dermatitis Press release
New Galderma research reveals more than half of women mistake menopause-related skin changes for signs of ageing Press release
Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older Press release
30 years of Restylane®: reshaping the aesthetics field through science-led, patient-centric innovation Press release
EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis Press release
Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies Press release
Galderma’s Restylane® Volyme™ demonstrates high effectiveness, satisfaction and a robust safety profile in Chinese patients with temple hollowing Press release
Galderma receives European Union approval for Restylane® Shaype™: the first-and-only bone-mimicking hyaluronic acid injectable for facial shaping Press release
Galderma launches Alastin® in Japan and key markets across Asia Pacific, expanding its footprint in the region Press release
Landmark global Galderma survey shows 9 out of 10 people are affected by skin quality concerns Press release
